Study data confirm uveitis implant efficacy, says Bausch & Lomb
This article was originally published in Clinica
Executive Summary
Bausch & Lomb (B&L) says that new data are now available to confirm that its Retisert eye implant for treating posterior uveitis reduces recurrence of the condition. The findings, together with those from the company's first pivotal trial of the product, will be submitted to the US FDA to support a marketing application for Retisert, which the company hopes to start commercialising next year.